| Outcome Measures: |
Primary: Pharmacokinetics parameters (Study Part I), For each subject at each Treatment Period, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose., 24h post-dose|Safety parameters (Study Parts II, III and IV), Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis)., Part II : 5 days ; Part III : 20 days ; Part IV : 20 days | Secondary: Safety parameters (Study Part I), Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis)., 12 days for male and 5 days for female|Pharmacokinetics parameters (Study Parts II, III and IV), Study Part II : For each subject of each dose level, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose. Study Part III and Study Part IV : Assuming a once daily administration, blood will be collected at the following time points: * Day 1 pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose. * Days 3, 7, 10, 11, 12 and 13 pre-dose. * Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose., Part II : 24h post-dose ; Part III : 15 days ; Part IV : 15 days
|
